Scientists reveal structure of amino acid transporter involved in cancer

June 05, 2018

The human glutamine transporter ASCT2 is upregulated in several forms of cancer. It is also the docking platform for a wide range of pathogenic retroviruses. A team of University of Groningen scientists have used cryo-electron microscopy to elucidate the structure of the protein, which may generate leads for drug development. The results were published in Nature Structural & Molecular Biology on 5 June.

In human cells, the ASCT2 protein imports the amino acid glutamine and maintains the amino acid balance in many tissues. The amount of ASCT2 is increased in several types of cancer, probably because of an increased demand for glutamine. Furthermore, several types of retrovirus infect human cells by first docking on this protein.

Insights

ASCT2 is part of a larger family of similar transporters. To understand how this family of amino acid transporters works, and to help design drugs that block glutamine transport by ASCT2 or its role as a viral docking station, University of Groningen scientists have resolved the 3D structure of the protein. They resorted to the technique of single particle cryo-electron microscopy, as they did not succeed in growing crystals from the protein, which are required for X-ray diffraction studies. The human gene for ASCT2 was expressed in yeast cells, and the human protein was purified for imaging.

The structure was determined at a resolution of 3.85 Å, which revealed striking new insights. 'It was a challenging target, as it is rather small for cryo-EM', says Assistant Professor of Structural Biology Cristina Paulino, who is head of the University's Cryo-EM unit. 'But it also has a nice symmetric trimeric structure, which helps.'

Lift-structure

The cryo-EM images reveal a familiar type of 'lift-structure', in which part of the protein travels up and down through the cell membrane. In the upper position, substrate enters the lift, which then moves down to release the substrate inside the cell. The structure of ASCT2 revealed the lift in the lower position. 'To our surprise, this part of the protein was further down then we had ever seen before in similar protein structures', says Professor of Biochemistry Dirk Slotboom. 'And it was rotated. It had been thought that the substrate enters and leaves the lift through different openings, but our results suggest it might well use the same opening.'

This information could help design molecules that stop glutamine transport by ASCT2, says Albert Guskov, Assistant Professor in Crystallography. 'Some tests in mice with small molecules that block transport have been published.' Blocking glutamine transport would be a way to kill cancer cells. 'This new structure allows for a more rational design of transport inhibitors.'

Spikes

Another surprise observation are the spikes that protrude on the outside of each of the three monomers. 'They have never been seen before', says Slotboom. 'These are the places where retroviruses dock.' This is consistent with mutagenic studies performed by others. Again, knowing the shape of the spikes could help design molecules which block the viruses from docking.

The protein structure was resolved in about four months, which is remarkably fast for cryo-EM. Different scientists, each with their own specialty, worked in parallel, which speeded up the process. Furthermore, PhD student Alisa Garaeva, who is first author of the paper, played a central role in ensuring the project ran efficiently.

Future studies will be done to capture ASCT2 in different configurations, for example inside a lipid bilayer rather than the detergent micelles used in the present study and with the lift in different positions. Paulino, Slotboom and Guskov conclude that studying different states will help them understand how this protein functions.
-end-
Reference: Alisa A. Garaeva, Gert T. Oostergetel, Cornelius Gati, Albert Guskov, Cristina Paulino & Dirk J. Slotboom: Cryo-EM structure of the human neutral amino acid transporter ASCT2. Nature Structural & Molecular Biology. 5 June 2018

University of Groningen

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.